Seaside Ventures

Promising results and progress in chronic cough treatment ?? Sensory Cloud, Inc. and Hyfe announced promising results from a study showing that Sensory Cloud’s inhaled #alkaline HDS #aerosol significantly reduced #cough frequency in patients with refractory chronic cough (RCC), with no significant adverse events. Read more ?? https://lnkd.in/eSDuzrtT Imperial College London David Edwards Tal Wenderow Mark Grande Angela Maglione Deen Bhatta Andreas Bilstein Andrew Levitch Ville Kurki Alka Batycky PhD #refractorychroniccough #chroniccough Sensory Cloud, Inc. #rcc #inhaledalkaline

We're excited to announce our participation in Paterna Biosciences’ $6M Seed Round, led by SpringTide Ventures, with additional support from top investors in the biotech space. Paterna is pioneering an approach to male infertility through in vitro spermatogenesis (IVS), with a focus on enhancing fertility outcomes by generating viable sperm from stem cells. Founded by reproductive health leaders like Dr. Alex Pastuzak, Brad Cairns, Ph.D., and Dr. Jim Hotaling, Paterna is uniquely positioned to address genetic factors underlying male infertility. By developing technology that enables natural sperm maturation, Paterna offers a promising new avenue for couples facing male infertility challenges.

We’re excited to announce our latest investment in Calorify, marking our first step into the metabolic health space. Calorify utilizes doubly labeled water (DLW) technology to provide the most precise, real-time insights into energy expenditure for clinical, research, and personal health applications. By making DLW technology more accessible and practical, Calorify is setting a new standard for metabolic measurement in a range of settings, from clinical trials and sports science to everyday health management. Their platform empowers healthcare providers, researchers, and individuals to accurately track energy expenditure, which is crucial for understanding and managing metabolic conditions such as obesity, diabetes, and other related disorders. What sets Calorify apart is their ability to deliver DLW technology—traditionally limited to specialized research—through an affordable, user-friendly platform. This breakthrough enables broader adoption and has the potential to democratize access to high-quality metabolic data, making it a valuable tool for optimizing health outcomes across diverse populations.

?? New Product Launch from ZBiotics ?? Today, ZBiotics has introduced its second product, Sugar-to-Fiber Probiotic Drink Mix. This product is designed to address common deficiencies in the American diet by converting dietary sugar into prebiotic fiber throughout the day, supporting better gut health. Developed by a team of PhD microbiologists, Sugar-to-Fiber utilizes genetic engineering to transform sugar into a special type of fiber (levan). This innovation aims to help fill the gap in fiber intake, a challenge for many on ultra-processed Western diets, where ~95% of Americans are fiber deficient. Key benefits of Sugar-to-Fiber include: ? Improved digestion and nutrient absorption ? Enhanced immune function ? Increased microbiome diversity For more information or to purchase, visit zbiotics.com.

We're thrilled to share our participation in ZBiotics’ $12M Series A, alongside Spring Tide Capital, Access Capital, Seamless Capital, and Goat Rodeo Capital. ZBiotics has launched the world's first genetically engineered probiotic designed to tackle the modern challenges of living. This round increases ZBiotics' total funding of $26.1M to date. Under the guidance of microbiology expert Zachary Abbott, Ph.D., ZBiotics is setting new standards in health technology. By focusing on genetically engineered probiotics, ZBiotics introduces a novel approach to solving health issues, starting with its flagship product, the Pre-Alcohol Probiotic Drink. This product is designed to mitigate the after-effects of alcohol by breaking down acetaldehyde, a toxic byproduct of alcohol responsible for hangovers. ZBiotics stands out in a crowded market by offering real solutions to modern lifestyle challenges. Through patented technology and a focus on transparency and ethical responsibility, ZBiotics is not merely introducing a product but pioneering a new category of adaptability in biotech solutions. Their work represents a significant advancement in consumer health, paving the way for future products that address diet, sleep, and athletic performance. ZBiotics differentiates itself with a commitment to scientific integrity, responsible genetic engineering, and a consumer-first approach. This investment underscores our belief in ZBiotics' mission to blend sophisticated science with practical applications, redefining consumer health.

Check out our July 2024 newsletter! This edition features milestones from portfolio companies like Samphire Neuroscience, Plan A (NEXT Life Sciences, Inc.), and ZBiotics. We also share details about our upcoming Seaside Hike in Los Angeles and our latest health & wellness insights. Plus, we have an exciting co-investment opportunity in the sleep technology space. Read more here:

Check out our June 2024 newsletter! This edition features significant milestones from portfolio companies like Pangea Bio and Flaus, along with insightful op-eds from our team on the future of health and wellness. Plus, discover which of our portfolio companies are raising new rounds. Read more now below: